IMMUNE RECONSTITUTION IN PATIENTS WIHT B-NON HODGKIN LYMPHOMA (B-NHL) TREATED WITH RITUXIMAB, CHEMOTHERAPY OR BOTH - A COHORT STUDY

被引：0
|
作者：
Afonso, A. [1 ]
机构：
[1] Inst Portugues Oncol Lisboa Francisco Genti, Lisbon, Portugal
来源：
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL | 2010年 / 95卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
1559
引用
收藏
页码：617 / 618
页数：2
相关论文
共 50 条
  • [41] RITUXIMAB-BENDAMUSTINE-DEXAMETHASONE (RD-BENDA) FOLLOWED BY RITUXIMAB CONSOLIDATION AND LENALIDOMIDE MAINTENANCE FOR FRAIL ELDERLY PATIENTS WITH NEWLY AGGRESSIVE B-NON HODGKIN LYMPHOMA
    Pezzullo, L.
    Bruno, A.
    Rosamilio, R.
    Bianco, R.
    Fontana, R.
    Ferrara, I.
    Mettivier, L.
    Guariglia, R.
    Martorelli, M. C.
    Serio, B.
    Selleri, C.
    HAEMATOLOGICA, 2017, 102 : 113 - 114
  • [42] PROLONGATION OF THE TREATMENT OF MAINTENANCE WITH RITUXIMAB IN PATIENTS WITH INDOLENT NON HODGKIN B LYMPHOMA
    Nunez Garcia, A.
    Sevil Puras, F. J.
    Aguilar Franco, C.
    Faura Petisco, M., V
    HAEMATOLOGICA, 2015, 100 : 267 - 268
  • [43] Phase I study of a novel humanized anti-CD20 antibody, BM-ca, in patients (pts) with relapsed or refractory indolent B-cell non-Hodgkin lymphoma (B-NHL) pretreated with rituximab
    Tobinai, Kensei
    Ogura, Michinori
    Maruyama, Dai
    Suzuki, Tatsuya
    Kobayashi, Yukio
    Uchida, Toshiki
    Fukuhara, Suguru
    Oyama, Takashi
    Fukuzaki, Tomoharu
    Komatsu, Yasuhiko
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [44] Risk of Reverse Seroconversion of Hepatitis B Virus Surface Antigen in Rituximab-Treated Non-Hodgkin Lymphoma Patients A Large Cohort Retrospective Study
    Hsiao, Liang-Tsai
    Chiou, Tzeon-Jye
    Gau, Jyh-Pyng
    Yang, Ching-Fen
    Yu, Yuan-Bin
    Liu, Chun-Yu
    Liu, Jin-Hwang
    Chen, Po-Min
    Tzeng, Cheng-Hwai
    Chan, Yu-Jiun
    Yang, Muh-Hwa
    Huang, Yi-Hsiang
    MEDICINE, 2015, 94 (32)
  • [45] Gender and Race As Prognostic Factors In Patients Treated With Rituximab For B-Cell Non-Hodgkin Lymphoma
    Goldfinger, Mendel
    Aparo, Santiago
    Gundabolu, Krishna
    Barta, Stefan K.
    BLOOD, 2013, 122 (21)
  • [46] Pharmacokinetics of rituximab associated with CHOP chemotherapy in B-cell non-Hodgkin lymphoma
    Blasco, Helene
    Chatelut, Etienne
    de Bretagne, Isabelle Benz
    Congy-Jolivet, Nicolas
    Le Guellec, Chantal
    FUNDAMENTAL & CLINICAL PHARMACOLOGY, 2009, 23 (05) : 601 - 608
  • [47] Phase 2 study of bortezomib and rituximab in patients with indolent non-Hodgkin's lymphoma (NHL)
    Saleh, M
    Dakhil, S
    deVos, S
    Donnelly, DP
    Glenn, M
    Hart, L
    Reese, D
    Gregory, S
    Holladay, S
    McLaughlin, P
    Zhang, T
    Boral, A
    Wyld, P
    Goy, A
    ANNALS OF ONCOLOGY, 2005, 16 : 136 - 136
  • [48] Phase II study of denileukin diftitox (ONTAK®) in patients with relapsed/refractory B-cell Non-Hodgkin's lymphoma (B-NHL) and poor bone marrow reserve.
    Czuczman, Myron S.
    Pinter-Brown, Lauren
    Lechowicz, Mary Jo
    Bartlett, Nancy
    Lazarus, Hillard
    Lister, John
    Goy, Andre
    Kahanic, Stephen
    Rosen, Peter
    Acosta, Mark
    BLOOD, 2006, 108 (11) : 263B - 264B
  • [49] Radioimmunotherapy with 131I-rituximab for patients with relapsed/refractory B-cell non-Hodgkin's lymphoma (NHL)
    Kang, Hye J.
    Lee, Seung S.
    Kim, Kyeong M.
    Choi, Tae H.
    Cheon, Gi J.
    Kim, Won S.
    Suh, Cheolwon
    Yang, Sung H.
    Lim, Sang M.
    ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2011, 7 (02) : 136 - +
  • [50] Biallelic inactivation of TP53 is associated with an increased risk of relapse in paediatric B-cell Non-Hodgkin lymphoma (B-NHL)
    Newman, Alexander M.
    Zaka, Masood
    Zhou, Peixun
    Erhorn, Amy
    Barnard, Amy
    Crossland, Rachel E.
    Wilkinson, Sarah
    Enshaei, Amir
    Taj, Mary
    Wood, Katrina
    Televantou, Despina
    Turner, Suzanne D.
    Burke, Amos
    Harrison, Christine J.
    Bomken, Simon
    Bacon, Chris M.
    Rand, Vikki
    BRITISH JOURNAL OF HAEMATOLOGY, 2018, 182 : 60 - 60
12345